Antidote: H1N1 flu vaccine

Share this article:
There is a lot of confusion about this year's flu vaccine, in part because last year's novel H1N1 mild flu pandemic broke the usual mold on flu. The flu season came very early last year, in keeping with pandemic strains, and it had a predilection for younger patients, also typical of new flu viruses. And finally, though 43-89 million Americans were infected according to the CDC, there were only approximately 12,000 deaths, one-third of the usual number for seasonal flu, when it is the elderly who are predominately affected.                                                          

This year we are anticipating a more typical flu season, with the novel H1N1 receding into the background.  Though there appears to be an early surplus of vaccine, I am reluctant to vaccinate early—flu doesn't generally peak until February or March, and the vaccine is most effective for the first six months after giving it.     

I do not expect children or pregnant women to have a greater tendency to contract the flu this year. But I do believe that the CDC is right to recommend that all children over the age of 6 months receive flu shots. Children are super spreaders of the disease. If children are vaccinated, there will be much less flu around.

Similarly, I agree with the American Academy of Pediatrics that flu vaccines be mandatory for all healthcare workers.  Consider that despite all the attention that H1N1 swine flu received last year, only 37% of healthcare workers received this vaccine.                                                                               

As research proceeds on new and better flu vaccines, in the meantime, we can protect ourselves and those around us by taking the seasonal flu vaccine.

Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?